TrianglePembrolizumab (NCT07594015)
Pembrolizumab trial for Recurrent Endometrial Cancer (NCT07594015). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult women with recurrent, mismatch-repair-proficient endometrial cancer after progression on or following first-line maintenance immunotherapy started with carboplatin-based chemotherapy. Tumor sequencing is required; previous VEGFR inhibitors or more than one immunotherapy line exclude participation.
The idea: combine pembrolizumab infusions every three weeks with oral lenvatinib. Pembrolizumab releases an immune checkpoint; lenvatinib blocks VEGFR2 signals involved in blood-vessel growth. Researchers assess tumor shrinkage or sustained stable disease and safety. Treatment continues for two years unless stopped earlier.
This phase 2 study plans 46 patients. Navya Nair leads Miami's recruiting site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.